GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lisata Therapeutics
Lisata Therapeutics is an oncology company developing drugs to improve drug delivery to tumors. Its stock price is a bet on its technology platform. Its price is volatile and driven by news of clinical trials and partnerships.
Share prices of companies in the market segment - Oncology platforms
Lisata Therapeutics develops drugs that modify the tumor microenvironment to make it more susceptible to standard therapy. We've classified it as an "Oncology Platform." The chart below shows how the market values innovative cancer treatment approaches.
Broad Market Index - GURU.Markets
Lisata Therapeutics is an oncology company developing drugs that target the tumor microenvironment to improve treatment effectiveness. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Lisata shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
LSTA - Daily change in the company's share price Lisata Therapeutics
For Lisata Therapeutics, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reactions to news about clinical trials of its drug delivery platform and serves as a risk assessment parameter.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Lisata Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with LSTA's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Lisata Therapeutics is a biotech company developing drugs to improve drug delivery to tumors. Its shares are driven by research news. This high volatility, driven by innovation, is a significant contributor to the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lisata Therapeutics
For Lisata Therapeutics, year-over-year performance is a story about the development of its platform for improving drug delivery to tumors. Its 12-month market cap depends entirely on clinical trial data, where it must prove that its technology can improve the effectiveness of existing cancer treatments, opening up a large market for it.
Annual dynamics of market capitalization of the market segment - Oncology platforms
As an early-stage biotech, Lisata is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drug delivery platform. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lisata Therapeutics, which develops drugs to improve cancer therapy, is betting on treatment synergies. Its shares will react sharply to clinical trial data demonstrating the effectiveness of its approach. Its performance relative to the market illustrates the high level of investor hopes for its complementary technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its primary therapeutic platform triggers an immediate and strong investor reaction, typical of biotech.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
This chart reflects the dynamics of the volatile biotech sector. For Lisata, a clinical-stage oncology company, it's the backdrop. Its movements illustrate how clinical trial successes and failures influence investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where news about clinical trials trumps overall market trends. The chart below shows the pulse of the broader market. Does Lisata Therapeutics move in sync with the market, or are breakthroughs in its R&D pipeline creating a completely independent story for the stock?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lisata Therapeutics
Lisata Therapeutics, an oncology company developing drugs to improve drug delivery to tumors, is extremely sensitive to scientific news. Its weekly stock price is reflecting clinical trial data confirming that its technology could make other cancer drugs more effective.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Lisata Therapeutics operates in the highly competitive oncology sector, where investor sentiment drives global sentiment. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will reveal whether LSTA is mired in the general flow of biotech speculation or whether its unique drug delivery technology sets it apart.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Lisata Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how LSTA shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
LSTA - Market capitalization of the company Lisata Therapeutics
Lisata Therapeutics' market cap is a bet on improving drug delivery to tumors. The company is developing a technology designed to make tumors more permeable to chemotherapy. Its valuation chart reflects how investors view this supportive, yet potentially important, technology in oncology.
LSTA - Share of the company's market capitalization Lisata Therapeutics within the market segment - Oncology platforms
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to solid tumors. Its market share in the oncology sector is based on this supporting technology. The chart shows how its approach, which "hacks" tumor defenses, is in demand to improve the effectiveness of existing therapies.
Market capitalization of the market segment - Oncology platforms
Lisata Therapeutics develops drugs that "hack" tumor defenses, making them more susceptible to chemotherapy. The chart below shows the market capitalization of oncology platforms. This represents an estimate of the innovative approach that could improve the effectiveness of existing treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Lisata Therapeutics develops drugs that make tumors more resistant to chemotherapy. Its market capitalization is a bet on this synergistic approach. The chart below shows the economic weight of companies improving the effectiveness of cancer treatment.
Book value capitalization of the company, segment and market as a whole
LSTA - Book value capitalization of the company Lisata Therapeutics
Lisata Therapeutics is based on drug delivery technology. The company's book value reflects its patents for the CendR platform, which helps drugs penetrate deep into tumors, and funds for clinical trials of this platform in combination with other drugs. The chart below shows the financial basis on which this complementary oncology technology is built.
LSTA - Share of the company's book capitalization Lisata Therapeutics within the market segment - Oncology platforms
Lisata Therapeutics, an oncology company, is focused on R&D. Its laboratories are its main tangible asset. The S_BCap_Seg chart shows its small share of physical infrastructure, which is typical for a biotech company.
Market segment balance sheet capitalization - Oncology platforms
Lisata Therapeutics develops drugs to improve drug delivery to tumors. Its value lies in this unique technology and associated patents. A book value chart shows that its assets are almost entirely intangible, reflecting a focus on research rather than manufacturing.
Book value of all companies included in the broad market index - GURU.Markets
Lisata's assets are a technology for delivering drugs deep into tumors. The company's book value reflects its rights to the CendR platform and its clinical research capital. This is the material base for creating drugs that act as a "Trojan horse," helping other cancer drugs better penetrate their targets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lisata Therapeutics
Lisata Therapeutics develops drugs that "hack" the tumor microenvironment to improve the delivery of anti-cancer drugs. Its book value is small. Its market capitalization reflects its unique scientific platform and its potential to improve the effectiveness of existing cancer treatments.
Market to book capitalization ratio in a market segment - Oncology platforms
Lisata Therapeutics develops drugs to improve drug delivery to tumors. Its value lies in this complementary technology. The chart shows how the market perceives the potential of its platform to enhance the effectiveness of existing cancer treatments.
Market to book capitalization ratio for the market as a whole
Lisata Therapeutics develops drugs that make tumors more susceptible to standard therapy. The company's value lies in its innovative approach and patents. The chart shows how its market valuation reflects hopes for scientific breakthroughs in oncology, creating a significant gap with its book value.
Debts of the company, segment and market as a whole
LSTA - Company debts Lisata Therapeutics
Lisata Therapeutics, an oncology company, is using debt to finance its technology that improves drug delivery to tumors. This chart shows how the company is raising funds to conduct clinical trials in which its lead drug is used in combination with other cancer therapies.
Market segment debts - Oncology platforms
Lisata Therapeutics is a clinical-stage oncology company developing technology to improve drug delivery to tumors. Its future depends on the results of clinical trials and its ability to attract partners or investors. This chart shows its cash reserves, which determine how long it can continue its R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lisata Therapeutics
Lisata Therapeutics develops drugs to improve drug delivery to tumors. This chart shows how the company finances its unique technology platform. Raising debt during the research stage suggests a high expectation that its technology will be adopted by other pharmaceutical companies to improve the effectiveness of their drugs.
Market segment debt to market segment book capitalization - Oncology platforms
Lisata Therapeutics develops platforms for more efficient drug delivery to tumors. This biotech sector chart shows how companies finance their platform technologies. It helps assess whether a company's debt represents an investment in a technology with broad potential for application in oncology.
Debt to book value of all companies in the market
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to solid tumors. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance companies with innovative platforms but long development cycles determines Lisata's future.
P/E of the company, segment and market as a whole
P/E - Lisata Therapeutics
Lisata Therapeutics develops drugs that modify the tumor microenvironment to make it more susceptible to chemotherapy. This chart reflects the company's belief in its innovative approach to cancer treatment. Its value reflects the degree of risk investors are willing to take in the hope that the company's technology can overcome one of the main challenges in oncology: tumor resistance.
P/E of the market segment - Oncology platforms
Lisata Therapeutics is a biotech company. This chart shows the average P/E ratio for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its approach to cancer treatment compared to the average prospects of other oncology developments.
P/E of the market as a whole
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to solid tumors. Its technology aims to make existing treatments more effective. This chart shows the sentiment in the biotech sector. The company's valuation depends on the success of its technology in clinical trials in combination with other drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lisata Therapeutics
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to solid tumors. The graph reflects speculative revenue expectations, which depend on the success of clinical trials, which should demonstrate that its technology can significantly improve the effectiveness of existing chemotherapy.
%20P%2FE%20Lisata%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lisata-Therapeutics&v=1772620127526 "Chart of the company's future (projected) P/E Lisata Therapeutics")
Future (projected) P/E of the market segment - Oncology platforms
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to solid tumors. This chart shows how its future revenue expectations compare to the industry average, reflecting its potential as an adjuvant therapy that could enhance the effectiveness of existing treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772620127534 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to tumors. This is an adjunctive technology that can enhance the effectiveness of other treatments. The company's success depends on partnerships with major pharmaceutical companies and clinical trial data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772620127554 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lisata Therapeutics
Lisata Therapeutics is a clinical-stage biotechnology company developing drugs to improve the delivery of anticancer drugs directly to tumors. Its financial indicators reflect research and development expenditures. This chart illustrates investments aimed at improving the effectiveness of existing cancer treatments.
Profit of companies in the market segment - Oncology platforms
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing drugs that modify the tumor microenvironment to enhance the effectiveness of cancer therapy. This graph shows the profitability of its oncology platforms. Its innovative approach can be used in combination with other treatments, creating significant potential for partnerships.
Overall market profit
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs directly to tumors. The company's success depends on the effectiveness of its platform and the results of clinical trials. This chart illustrates the general economic cycles within which Lisata is working to solve a fundamental problem in oncology, which could create enormous value.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lisata Therapeutics
Lisata Therapeutics develops drugs that modify the tumor microenvironment to make it more susceptible to standard therapy. This chart reflects analysts' future earnings expectations, based on the potential of this innovative platform to improve cancer treatment outcomes. It demonstrates the market's confidence in this new approach to oncology.
%20profit%20of%20the%20company%20Lisata%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lisata-Therapeutics&v=1772620127648 "Graph of future (projected) profit of the company Lisata Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology platforms
Lisata Therapeutics, Inc. develops innovative treatments for solid tumors and other serious diseases. This chart shows revenue projections for its oncology platforms. It reflects expectations for new technologies that can improve the efficiency of drug delivery directly to tumors.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772620127650 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Lisata Therapeutics develops drugs to treat cancer. For a company at the research stage, market profit forecasts are important as an indicator of funding availability. During periods of economic optimism, investors are more willing to invest in risky biotech companies, which is vital for advancing their therapeutic platforms.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772620127667 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lisata Therapeutics
Lisata Therapeutics develops drugs to improve drug delivery to tumors. Currently in the clinical stage, it has no stable revenue. Its P/S will become relevant once its technology is validated and licensed by major pharmaceutical companies, reflecting its value.
P/S market segment - Oncology platforms
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs directly to solid tumors. Their technology could enhance the effectiveness of existing chemotherapy. This chart shows the market perception of their amplification platform and its potential for partnerships with major pharmaceutical companies and revenue generation.
P/S of the market as a whole
Lisata Therapeutics develops drugs that modify the tumor microenvironment to make it more susceptible to other therapies. The company has no revenue, and its valuation is based on the potential of its platform. This chart, showing the estimated real revenue, highlights the speculative nature of investing in Lisata.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lisata Therapeutics
Lisata Therapeutics develops drugs that modify the tumor microenvironment to make it more susceptible to chemotherapy. This graph reflects investor expectations for future revenue from this maintenance therapy, which could significantly improve the effectiveness of existing cancer treatments.
%20P%2FS%20Lisata%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lisata-Therapeutics&v=1772620127755 "The graph of the company's future (projected) P/S Lisata Therapeutics")
Future (projected) P/S of the market segment - Oncology platforms
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative treatments for solid tumors and other serious diseases. This chart shows how the market views the future potential of its oncology platforms. Comparisons with competitors reflect investor confidence in its scientific developments and clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772620127763 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Lisata Therapeutics develops drugs designed to improve the delivery of anticancer drugs directly to tumors. This adjuvant therapy can enhance treatment efficacy. This graph reflects overall sales expectations, and LSTA demonstrates how innovations aimed at improving existing treatments can have significant potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772620127779 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lisata Therapeutics
Lisata Therapeutics is a clinical-stage oncology company developing innovative methods for delivering drugs directly to tumors. Because its technologies are still in development, the company has no sales revenue. Any revenue shown in this chart likely comes from licensing or partnership agreements.
Sales of companies in the market segment - Oncology platforms
Lisata Therapeutics is a biotech company developing drugs to improve drug delivery to tumors. At this stage, its revenue is likely derived from partnerships. This chart allows investors to assess the financial support, which validates the potential of its scientific platform.
Overall market sales
Lisata Therapeutics develops drugs to improve drug delivery to tumors. Its success depends on the effectiveness of its platform and partnerships with other pharmaceutical companies. This market overview chart is not relevant to Lisata, whose value is created in the laboratory and determined by its potential to improve cancer treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lisata Therapeutics
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs directly to tumors. Its revenue forecast depends on the success of clinical trials in which its technology is used in combination with other treatment methods. This graph reflects expectations for its platform as a therapy enhancer.
%20sales%20of%20the%20company%20Lisata%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lisata-Therapeutics&v=1772620127811 "Schedule of future (projected) sales of the company Lisata Therapeutics")
Future (projected) sales of companies in the market segment - Oncology platforms
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs directly to tumors. This chart reflects projected revenues for the entire oncology platform segment. It helps assess the demand for technologies that enhance the effectiveness of existing chemotherapy, which is Lisata's unique offering.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772620127832 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to tumors. The company's success depends on the results of clinical trials and partnerships with major pharmaceutical companies. This graph of overall market expectations reflects the investment climate. A positive environment facilitates capital raising and encourages "big pharma" to invest in innovative platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772620127836 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lisata Therapeutics
Lisata Therapeutics is a biopharmaceutical company developing drugs to improve drug delivery to tumors. This chart reflects its current focus on research. It doesn't show revenue, but rather investments in developing its technology platform, the success of which determines future partnerships and developments.
Market segment marginality - Oncology platforms
Lisata Therapeutics develops innovative drugs designed to modify the tumor microenvironment and more effectively deliver anticancer agents. This chart shows the average profitability in the oncology platform sector. It serves as a benchmark for assessing the commercial potential of Lisata's technology to improve existing cancer treatments.
Market marginality as a whole
Lisata Therapeutics develops drugs to improve drug delivery to tumors. The company aims to make existing cancer treatments more effective. This gross profit chart does not reflect Lisata's potential, which depends on the success of its technology and partnerships with major pharmaceutical companies.
Employees in the company, segment and market as a whole
Number of employees in the company Lisata Therapeutics
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing drugs to improve drug delivery to tumors. Its small, focused team of scientists is working on innovative technology. This chart shows the size of the R&D team, which is focused on solving one of the key problems in oncology.
Share of the company's employees Lisata Therapeutics within the market segment - Oncology platforms
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments for solid tumors. This chart highlights its scientific focus. It reflects the percentage of oncologists and researchers working on a unique technology that helps drugs penetrate tumors that Lisata brings together under its wing.
Number of employees in the market segment - Oncology platforms
Lisata Therapeutics, Inc. develops innovative methods for delivering drugs directly to tumors. This chart shows the employment in the oncology platform sector. The growing number of scientists in this field reflects the search for ways to improve the effectiveness of chemotherapy and reduce its toxicity, a key focus for the Lisata platform.
Number of employees in the market as a whole
Lisata Therapeutics, Inc. is a biotechnology company developing innovative drug delivery methods for the treatment of oncology and other diseases. Efficient drug delivery is a key challenge in the pharmaceutical industry. This graph shows overall utilization, and such platform technologies can accelerate the development of the entire industry.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lisata Therapeutics (LSTA)
Lisata Therapeutics is an oncology company. Like other companies in the sector, its value is determined by its future potential. This chart shows the value investors place on each scientist working on breakthrough therapies. It's a pure valuation of intellectual capital, multiplied by hope.
%20of%20the%20company%20Lisata%20Therapeutics%20(LSTA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lisata-Therapeutics-LSTA&v=1772620127903 "Chart of market capitalization per employee (in thousands of dollars) of the company Lisata Therapeutics (LSTA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Lisata Therapeutics develops technologies to improve drug delivery to tumors. The market value per employee reflects the value of its CendR platform. This high figure suggests investors see significant potential in its ability to make existing cancer treatments more effective.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772620127916 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to tumors. This is a complementary, but potentially very important, technology. This chart shows how the market evaluates the team's scientific potential to create a product that could improve the effectiveness of existing cancer treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772620127919 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lisata Therapeutics (LSTA)
Lisata Therapeutics is a biotech company developing a platform to improve drug delivery inside solid tumors. It's an R&D business. This chart, in negative territory, shows how much capital is being burned per scientist trying to solve one of the main problems in oncology—delivery of the drug to the target.
%20Chart%20Lisata%20Therapeutics%20(LSTA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lisata-Therapeutics-LSTA&v=1772620127929 "Company Profit Per Employee (in thousands of dollars) Chart Lisata Therapeutics (LSTA)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Lisata Therapeutics develops drugs to improve the delivery of anticancer drugs to solid tumors. Their technology aims to enhance the efficacy of existing therapies. This graph illustrates the potential value of their platform. It shows how their amplifying technology could create significant value, boosting the profitability of the entire oncology industry.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772620127938 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Lisata Therapeutics is a biotech company developing drugs to improve drug delivery to solid tumors. Their CendR platform enables other drugs to better penetrate cancer cells. This chart reflects the R&D costs per employee required to develop this platform technology and test it in combination with other drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772620127942 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lisata Therapeutics (LSTA)
Lisata Therapeutics is a clinical-stage oncology company. This graph, showing zero revenue per employee, is typical for biotech. It reflects a phase when all efforts are focused on research. Successful commercialization of its drug delivery platform could lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lisata-Therapeutics-LSTA&v=1772620127944 "Sales chart per company employee Lisata Therapeutics (LSTA)")
Sales per employee in the market segment - Oncology platforms
Lisata Therapeutics (LSTA) is a biotech company developing platforms to improve drug delivery to solid tumors (CEND-1 technology). This chart shows the average revenue per employee in the pharmaceutical segment. For Lisata, which is in the R&D stage, comparing it to this benchmark (zero) demonstrates their focus on platform development rather than sales.
Sales per employee for the market as a whole
Lisata Therapeutics (LSTA) is a biotech company (oncology) developing a drug delivery technology for tumors. It's a clinical-stage R&D company with no revenue. This metric is irrelevant. Their entire value lies in the potential of their scientific platform and clinical trial data.
Short shares by company, segment and market as a whole
Shares shorted by company Lisata Therapeutics (LSTA)
Lisata Therapeutics is a biotech company developing drugs to improve tumor drug delivery (cancer treatment). This chart illustrates skepticism about their technology. Bears are betting that their approach will fail to prove effective in clinical trials, a common occurrence for drug delivery platforms.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lisata-Therapeutics-LSTA&v=1772620127972 "Short Shares Chart for the Company Lisata Therapeutics (LSTA)")
Shares shorted by market segment - Oncology platforms
Lisata (LSTA) is a biotech developing a technology that helps other drugs (chemotherapy) better penetrate tumors. This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that this "assistant" technology won't work. Investors doubt LSTA can prove that its approach truly improves treatment outcomes and isn't simply adding toxicity.
Shares shorted by the overall market
Lisata (LSTA) is a clinical-stage biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing LSTA won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lisata Therapeutics (LSTA)
Lisata Therapeutics is developing a platform to improve drug delivery directly to tumors. It's an "assistant" technology for oncology. This graph shows the partnership's "pulse." Investor interest is driven not so much by its own data as by news of collaborations with major pharmaceutical companies.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lisata-Therapeutics-LSTA&v=1772620128142 "RSI 14 indicator chart for the company's stock Lisata Therapeutics (LSTA)")
RSI 14 Market Segment - Oncology platforms
Lisata Therapeutics is a biotech company developing the CendR platform for tumor "breakthroughs." Their technology helps other cancer drugs penetrate deeper into solid tumors. This chart reflects the overall sentiment in the oncology sector. It helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Lisata (LSTA) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LSTA (Lisata Therapeutics)
Lisata Therapeutics (LSTA) develops innovative drugs designed to "unlock" the microenvironment of solid tumors, making them vulnerable to therapy. This chart shows the average target price. It reflects analysts' confidence in this oncology platform and its potential in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LSTA-Lisata-Therapeutics&v=1772620128174 "A chart showing analyst consensus forecasts for the expected stock price. LSTA (Lisata Therapeutics)")
The difference between the consensus estimate and the actual stock price LSTA (Lisata Therapeutics)
Lisata Therapeutics is an oncology company developing a cancer-targeting platform (CDE) that helps drugs penetrate solid tumors. This chart shows how far the current share price differs from the "fair" value predicted by analysts. This gap reflects experts' belief that Lisata's technology could become a key "partner" in improving the effectiveness of other cancer treatments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LSTA-Lisata-Therapeutics&v=1772620128175 "A chart showing the difference between the consensus forecast and the actual stock price. LSTA (Lisata Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Lisata Therapeutics is developing tumor "hackers"—drugs that help other drugs (such as chemotherapy) penetrate cancer cells. This chart reflects analysts' overall expectations across the oncology platform sector. It shows whether experts believe in the success of "combination" R&D approaches to cancer treatment.
Analysts' consensus forecast for the overall market share price
Lisata Therapeutics is a biotech company developing a platform (LSTA 1) that "opens" tumors so chemotherapy can penetrate them. This is a high-risk sector. This chart reflects the overall risk appetite in the market. For Lisata, a clinical-stage company, overall market optimism (as shown by the rising chart) is critical for attracting capital to fund research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lisata Therapeutics
Lisata Therapeutics is a biotech company working to hack tumors. Their R&D platform (CEND-1) is a Trojan horse designed to open up tumors from the inside, allowing other chemotherapy drugs to penetrate deeper. This graph is a clear indicator of their faith in R&D. It reflects their progress in clinical trials and their partnerships with big pharma.
AKIMA Market Segment Index - Oncology platforms
Lisata Therapeutics (LSTA) is developing a CDE platform designed to "reprogram" the tumor microenvironment and more effectively deliver drugs to hard-to-treat solid tumors. This chart shows the average composite index for the oncology platform segment. It allows investors to compare Lisata's unique tumor-penetrating strategy with the average.
The AKIM Index for the overall market
Lisata Therapeutics is a biotech company developing treatments for solid tumors and cardiovascular diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research company compares to overall economic trends.
